SynthesisFrontiers in medicine2026
Efficacy of desmopressin in reducing post-procedural bleeding among chronic kidney disease patients: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic kidney disease (CKD) is associated with uremic-related platelet dysfunction and a greater risk of perioperative bleeding. Desmopressin (DDAVP) is believed to improve platelet function and is used prophylactically to prevent post-operative bleeding, but with uncertain efficacy. In this research, we evaluated the efficacy of peri-procedural desmopressin administration in reducing bleeding complications in CKD patients. Methods: We searched PubMed, Scopus, and Embase up to August 2025 for randomized controlled trials (RCTs) and observational studies involving adult CKD patients undergoing non-surgical procedures who received peri-procedural desmopressin compared to a control group. Outcomes included overall bleeding events, hematoma, hematuria, hematocrit decline, transfusions, and interventions for bleeding control. Safety profile of hyponatremia was also assessed. Results: Of 1,744 records, a total of 7,944 participants from 21 studies were included. The meta-analysis showed that desmopressin did not significantly reduce overall bleeding events (OR 0.87, 95% CI 0.57-1.33). Similarly, there was no significant effect on the incidence of hematoma (OR 1.35, 95% CI 0.40-4.53) or hematuria (OR 1.44, 95% CI 0.50-4.12). Subgroup analysis restricted to randomized controlled trials (RCTs) demonstrated a significant reduction in overall bleeding events with desmopressin (OR 0.50, 95% CI 0.29-0.87). Further subgroup analysis by route of administration revealed that the intranasal route was associated with a significant reduction in total bleeding events (OR 0.52, 95% CI 0.32-0.84). Conclusion: This study suggests that desmopressin does not significantly reduce post-procedural bleeding in CKD patients. However, subgroup analyses restricted to RCTs, and the intranasal administration route suggest a reduction in bleeding complications. Systematic review registration: PROSPERO ID: CRD420251118342, URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251118342.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.